Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Citeline And Norstella Merge To Provide End-To-End Solutions For Pharma

Marriage Of Commercial And Clinical Capabilities

Executive Summary

Publisher’s Spotlight: Citeline, the publisher of Pink Sheet, is to merge with fellow pharmaceutical solutions provider Norstella.

Citeline is to merge with Norstella to form a new organization with the goal of becoming an end-to-end life sciences solutions provider, helping patients access life-saving therapies.

The merger of equals will bring together the Citeline business intelligence offerings with Norstella’s four pharmaceuticals solutions providers, Evaluate, MMIT, Panalgo and The Dedham Group, to help life sciences companies reach patients faster by providing clients with the intelligence and answers they need from early clinical development through to commercialization. The merger is expected to close in the second half of 2022.

Citeline (formerly Pharma Intelligence) – a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance – was recently acquired by Warburg Pincus from Informa for £1.9bn. It has a full portfolio of specialist brands, including the Citeline suite of products (Trialtrove, Sitetrove, Pharmaprojects) as well as Biomedtracker, Clinerion, Datamonitor Healthcare, Pink Sheet, Scrip, Generics Bulletin, In Vivo, Medtech Insight, HBW Insight, Skipta and TrialScope.  (Also see "Warburg Pincus Acquires Pharma Intelligence From Informa" - Pink Sheet, 1 Jun, 2022.) 

Together, Norstella and Citeline will help pharmaceutical manufacturers plan for and overcome barriers to access at every stage in the drug development life cycle. Citeline’s solutions, along with MMIT’s PAR data and other complementary Norstella data assets, will be able to use Panalgo’s Instant Health Data Analytics platform to produce answers to improve clients’ workflow and decision-making to help products get to market quicker.

“Accelerating innovation and ensuring that every patient gets the therapy that they need is our North Star,” said Norstella CEO Mike Gallup. “By bringing clinical and commercial intelligence together – along with real-world data – the combined company will be well positioned to deliver on its mission.”

Ramsey Hashem, CEO, and Jay Nadler, executive chair, of Citeline, added, “Ultimately, this marriage of commercial and clinical capabilities will advance the mission and enable the pharmaceutical C-suite to manage portfolio strategy like never before.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel